By 2015, transcatheter aortic valve replacement devices would make up almost 12 percent of all U.S. heart valve procedures. Such replacements are expected to contribute to a 6 percent average annual growth in U.S. heart valve procedures through 2015.
Of the three current trials on such devices, the PARTNER trial for Edwards Lifesciences’ SAPIEN valve is the most advanced. In Sept. 2010, Edwards Lifesciences released preliminary findings showing that the device was superior to standard therapy in reducing patient mortality.
Read the Millennium Research Group release on heart valve procedures.
Related Articles on Aortic Valve Repair:
5 Ways to Improve Anesthesia Quality in Surgery Centers
Rhode Island Hospital Anesthesiologist Found Liable for $500K in Malpractice Case
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
